Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00903422
First received: May 14, 2009
Last updated: February 23, 2015
Last verified: February 2015